What question did this study set out to answer?

This study aims to evaluate the efficacy and safety of Carfilzomib-augmented high-dose melphalan in multiple myeloma patients undergoing ASCT.

December 8, 2025BloodOpen Access

Carfilzomib Augmented with high-dose melphalan conditioning regimen Enhances Response in patients with multiple myeloma eligible for ASCT：an investigator-initiated, prospective, multicenter study

View Full Paper

Ask AI

Bookmark

Authors

Investigator-initiated trial shows Carfilzomib plus high-dose melphalan enhances response rates and safety in myeloma patients post-ASCT.

This study aims to evaluate the efficacy and safety of Carfilzomib-augmented high-dose melphalan in multiple myeloma patients undergoing ASCT.
Prospective, multicenter, single-arm study conducted in three centers in China
Included newly diagnosed transplant-eligible multiple myeloma patients aged ≥18 with ECOG performance status of 0-2
Patients received Carfilzomib at 27 mg/m²/day and high-dose melphalan at 200 mg/m² as conditioning before ASCT
100% of patients achieved ≥very good partial response at three months post-ASCT
The complete response rate was 65.7%, up from 40.0% pre-ASCT
Median time to neutrophil engraftment was 11 days and platelet engraftment was 13 days
No grade ≥3 adverse events reported; mild gastrointestinal issues were the only documented toxicities
97.0% of patients remained progression-free at a median follow-up of seven months

Wang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark